Spravato
NICE rejects Janssen’s depression spray Spravato for second time
Richard Staines
depression, Janssen, Johnson & Johnson, mental health, Spravato
0 Comment
Market Access/ News/ News/ News/ News/ Patients/ Sales and Marketing
NICE rejects J&J’s Spravato for treatment-resistant depression
Phil Taylor
depression, Janssen, Johnson & Johnson, Psychiatry, Spravato
0 Comment
J&J seeks wider use of its Spravato antidepressant in US
Phil Taylor
anti, central nervous system, depression, Johnson & Johnson, Psychiatry, Spravato
0 Comment
FDA approves Janssen’s ketamine-based nasal antidepressant
George Underwood
depression, esketamine, fda, Jansse, ketamine, Spravato
0 Comment